Drug Price Transparency for Medicare Patients Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jun 18, 2019)
Drug Price Transparency for Medicare Patients Act of 2019
This bill provides statutory authority for the Centers for Medicare & Medicaid Services rule titled "Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency," published on May 10, 2019. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule takes effect July 9, 2019.
What just happenedJun 19, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJun 18, 2019
- Jun 19, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jun 18, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Jun 18, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Jun 18, 2019IntroReferralIntro-H
Introduced in House
- Jun 18, 2019IntroReferral1000
Introduced in House